Elevation of interleukin-2 production in peripheral-blood lymphocytes by recombinant human granulocyte-colony-stimulating factor in ovarian-cancer patients during combination chemotherapy.
Interleukin-2 (IL-2) production and peripheral blood lymphocyte (PBL) subsets were measured in ovarian cancer patients who received cis-platinum based chemotherapy with or without recombinant human granulocyte colony stimulating factor (rhG-CSF). Additional treatment with rhC-CSF resulted in significant elevation of IL-2 production and highly differentiated natural killer (NK) cell counts, indicating that rhG-CSF may be helpful for enhancement of the cellular immunity in ovarian cancer patients.